reports hero background
Updated: Nov 20, 2026
ROIV Logo

Roivant Sciences

NASDAQ:ROIV·Stock Analysis Report
Day Range
$38.75 - $39.79
Market Cap
28.06B
P/E Ratio
0.0000
Avg Value
$31.32
Year Range
$20.14 - $42.50
$38.96$0.23 (0.59%)
1
General Information
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

2
Roivant Sciences (ROIV) Stock Graph
3
How We Grade Roivant Sciences (ROIV)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Roivant Sciences (ROIV) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how Roivant Sciences compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
INSMInsmed
N/A
N/A
N/A
21.57
UTHRUnited Therapeutics
51.44
72.35
54.9
82.59
GMABGenmab
13.67
58.01
N/A
98.45
INCYIncyte
50.49
57.29
N/A
81.56
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
6
Future Growth
Our estimate of future price growth is based on an aggregation of 8 analyst ratings over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $41.00 - $56.00 with an average of $49.33

25.79%
Expected movement for Roivant Sciences (ROIV) over the next 12 months
Based on these rankings

Recent Ratings for Roivant Sciences (ROIV)

Guggenheim
Date:
Nov 16, 2026
Action:
Maintains
Prev. Target:
$46.00
New Target:
$48.00
HC Wainwright & Co.
Date:
Nov 10, 2026
Action:
Maintains
Prev. Target:
$47.00
New Target:
$48.00
Citigroup
Date:
Oct 28, 2026
Action:
Maintains
Prev. Target:
$46.00
New Target:
$56.00
TD Cowen
Date:
Sep 9, 2026
Action:
Maintains
Prev. Target:
$50.00
New Target:
$55.00
Guggenheim
Date:
Sep 9, 2026
Action:
Maintains
Prev. Target:
$42.00
New Target:
$46.00
HC Wainwright & Co.
Date:
Sep 8, 2026
Action:
Maintains
Prev. Target:
$41.00
New Target:
$47.00
Jefferies
Date:
Sep 8, 2026
Action:
Maintains
Prev. Target:
$42.00
New Target:
$52.00
HC Wainwright & Co.
Date:
Aug 28, 2026
Action:
Reiterates
Prev. Target:
$41.00
New Target:
$41.00
7
Past Performance
How has Roivant Sciences (ROIV) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Roivant Sciences (ROIV) sharpe ratio over the past 5 years is 1.7859 which is considered to be above average compared to the peer average of 1.1108


BenzingaBenzinga Japan